LPAR2 and bladder transitional cell carcinoma: On the contrary, high LPAR2 expression was associated with improved prognosis in patients with BLCA (OS, HR = 0.68 [0.47 − 0.98], P = 0.036), CESC (OS, HR = 0.52 [0.32 − 0.86], P = 0.0089), HNSC (OS, HR = 0.65 [0.49 − 0.86], P = 0.0023), TYHM (OS, HR = 0.17 [0.04 − 0.68], P = 0.0046), UCEC (OS, HR = 0.59 [0.38 − 0.9], P = 0.014, RFS, HR = 0.54 [0.32–0.91], P = 0.018) and BRCA (RFS, HR = 0.8 [0.71–0.89], P = 7.3e − 05) (Fig. 4B, F, G, L, M, N).